Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study

被引:0
作者
Michela Silvestri
Francesca Marando
Anna Maria Costanzo
Umberto di Luzio Paparatti
Giovanni A. Rossi
机构
[1] Istituto Giannina Gaslini,Pediatric Pulmonology and Allergy Unit and Cystic Fibrosis Center
[2] AbbVie,undefined
[3] Medical Department,undefined
[4] Campoverde di Aprilia (LT),undefined
来源
Italian Journal of Pediatrics | / 42卷
关键词
Acute lower respiratory tract infection; Bronchiolitis; Gestational age;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 129 条
[1]  
Hall CB(2009)The burden of respiratory syncytial virus infection in young children N Engl J Med 360 588-98
[2]  
Weinberg GA(1986)Risk of primary infection and reinfection with respiratory syncytial virus Am J Dis Child 140 543-6
[3]  
Iwane MK(2010)Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 375 1545-55
[4]  
Blumkin AK(2000)Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid J Pediatr 137 865-70
[5]  
Edwards KM(2012)Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006 Pediatr Infect Dis J 31 5-9
[6]  
Staat MA(2009)Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005) Infection 37 109-16
[7]  
Glezen WP(2012)Paediatric intensive care admissions for respiratory syncytial virus bronchiolitis in France: results of a retrospective survey and evaluation of the validity of a medical information system programme Epidemiol Infect 140 608-16
[8]  
Taber LH(2003)Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry Pediatr Pulmonol 35 484-9
[9]  
Frank AL(2009)Committee on Infectious Disease: Policy statement – modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections Pediatrics 124 1694-701
[10]  
Kasel JA(2004)Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings Pediatr Infect Dis J 23 S193-201